WallStSmart

Bioceres Crop Solutions Corp (BIOX)vsICL Israel Chemicals Ltd (ICL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ICL Israel Chemicals Ltd generates 2803% more annual revenue ($7.41B vs $255.21M). ICL leads profitability with a 3.5% profit margin vs -96.9%. BIOX appears more attractively valued with a PEG of 1.95. ICL earns a higher WallStSmart Score of 59/100 (C).

BIOX

Hold

46

out of 100

Grade: D+

Growth: 5.3Profit: 2.0Value: 4.7Quality: 2.5
Piotroski: 3/9Altman Z: 0.63

ICL

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 5.0Value: 3.3Quality: 5.5
Piotroski: 2/9Altman Z: 2.12
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIOX.

ICLSignificantly Overvalued (-24.5%)

Margin of Safety

-24.5%

Fair Value

$4.62

Current Price

$5.60

$0.98 premium

UndervaluedFair: $4.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIOX2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

ICL2 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
39.5%8/10

Earnings expanding 39.5% YoY

Areas to Watch

BIOX4 concerns · Avg: 3.0/10
PEG RatioValuation
1.954/10

Expensive relative to growth rate

Market CapQuality
$31.30M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-359.8%2/10

ROE of -359.8% — below average capital efficiency

ICL4 concerns · Avg: 3.3/10
P/E RatioValuation
26.6x4/10

Moderate valuation

Return on EquityProfitability
4.3%3/10

ROE of 4.3% — below average capital efficiency

Profit MarginProfitability
3.5%3/10

3.5% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BIOX

The strongest argument for BIOX centers on Price/Book, EPS Growth.

Bull Case : ICL

The strongest argument for ICL centers on Price/Book, EPS Growth. Revenue growth of 14.5% demonstrates continued momentum.

Bear Case : BIOX

The primary concerns for BIOX are PEG Ratio, Market Cap, Piotroski F-Score. Debt-to-equity of 3.55 is elevated, increasing financial risk.

Bear Case : ICL

The primary concerns for ICL are P/E Ratio, Return on Equity, Profit Margin. Thin 3.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

BIOX profiles as a turnaround stock while ICL is a value play — different risk/reward profiles.

ICL carries more volatility with a beta of 0.95 — expect wider price swings.

ICL is growing revenue faster at 14.5% — sustainability is the question.

Monitor AGRICULTURAL INPUTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ICL scores higher overall (59/100 vs 46/100) and 14.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioceres Crop Solutions Corp

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Bioceres Crop Solutions Corp.

ICL Israel Chemicals Ltd

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

ICL Group Ltd, is a company specialized in minerals and chemical products worldwide. The company is headquartered in Tel Aviv, Israel.

Visit Website →

Want to dig deeper into these stocks?